These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 21338872)
21. Neurocognitive enhancement: what can we do and what should we do? Farah MJ; Illes J; Cook-Deegan R; Gardner H; Kandel E; King P; Parens E; Sahakian B; Wolpe PR Nat Rev Neurosci; 2004 May; 5(5):421-5. PubMed ID: 15100724 [No Abstract] [Full Text] [Related]
22. Enhancing cognition in the intellectually intact. Whitehouse PJ; Juengst E; Mehlman M; Murray TH Hastings Cent Rep; 1997; 27(3):14-22. PubMed ID: 9219019 [TBL] [Abstract][Full Text] [Related]
23. Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. Sahakian BJ; Morein-Zamir S Lancet Psychiatry; 2015 Apr; 2(4):357-62. PubMed ID: 26360089 [TBL] [Abstract][Full Text] [Related]
24. Part II. Cognitive domains for pharmacological intervention: implications for neuropsychiatric and neurological illnesses. Handb Exp Pharmacol; 2015; 228():157-9. PubMed ID: 26317140 [No Abstract] [Full Text] [Related]
25. [Can intelligence be increased with drugs?]. Virsu V Duodecim; 2000; 116(15):1525-6. PubMed ID: 12001471 [No Abstract] [Full Text] [Related]
26. On the trail of a cognitive enhancer for the treatment of schizophrenia. Stip E; Chouinard S; Boulay LJ Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228 [TBL] [Abstract][Full Text] [Related]
27. [The pharmacotherapy of the cognitive disorders in Alzheimer's disease. Guidelines for rational drug use--a review]. Strnad J; Bahro M Dtsch Med Wochenschr; 2000 Jul; 125(27):835-9. PubMed ID: 10929539 [No Abstract] [Full Text] [Related]
30. New drug development for cognitive enhancement in mental health: challenges and opportunities. Insel T; Krystal J; Ehlers M Neuropharmacology; 2013 Jan; 64():2-7. PubMed ID: 23145450 [No Abstract] [Full Text] [Related]
31. [Pharmacologic treatment for cognitive disorders: an update]. Lestage P Therapie; 2000; 55(4):507-12. PubMed ID: 11098728 [TBL] [Abstract][Full Text] [Related]
33. Utilization of the Dementia Rating Scale-2 and cognitive enhancers in the diagnosis and treatment of cognitive disorders and dementia. Caston JC; Diehl LA; Hedgepath AW J S C Med Assoc; 2004 Feb; 100(2):32-8. PubMed ID: 15040232 [No Abstract] [Full Text] [Related]
35. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Boot BP; Partridge B; Hall W Neurocase; 2012 Jun; 18(3):181-4. PubMed ID: 22007842 [TBL] [Abstract][Full Text] [Related]